SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible
Securities Fraud Violations by Certain Officers and Directors of Infinity Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”)
(NASDAQ: INFI) concerning possible violations of federal securities laws.
On June 14, 2016, Infinity announced a restructuring that would reduce its workforce by 21% in the wake of disappointing
drug-study results. While a Phase 2 study of its treatment for non-Hodgkin lymphoma met its primary endpoint of overall response
rate, the Company said it hoped it would provide a larger clinical benefit. Upon this news, shares of Infinity were down more than
69% on intraday trading. To obtain additional information about the investigation, go to:
http://zlk.9nl.com/infinity-pharmaceuticals-infi
or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone
at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud,
and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee
similar outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160614006255/en/